Brief: Aurobindo Pharma Receives USFDA Approval For Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets
07/04/2026 13:50
April 7 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - RECEIVES USFDA APPROVAL FOR DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS Source text: ID:nNSE1YtdYk Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11